eflornithine has been researched along with Thrombopenia in 8 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eflornithine was offered as compassionate treatment of 33 episodes of Pneumocystis carinii pneumonia in 31 patients with acquired immunodeficiency syndrome who were intolerant of and/or unresponsive to conventional trimethoprim-sulfamethoxazole or pentamidine therapy." | 7.68 | Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. ( Boylen, CT; Gilman, TM; Heseltine, PN; Paulson, YJ; Sharma, OP, 1992) |
| "The dose limiting toxicity of difluoromethylornithine (DFMO), when administered by continuous infusion, is thrombocytopenia." | 7.68 | Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. ( Ajani, JA; Grossie, VB; Nishioka, K; Ota, DM, 1991) |
| "The purpose of this study was to evaluate the effect of a concomitant infusion of ornithine on the difluoromethylornithine (DFMO)-induced thrombocytopenia and antitumor activity." | 7.67 | Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. ( Ajani, JA; Chang, TH; Grossie, VB; Nishioka, K; Ota, DM; Patenia, D, 1989) |
| "Eflornithine was offered as compassionate treatment of 33 episodes of Pneumocystis carinii pneumonia in 31 patients with acquired immunodeficiency syndrome who were intolerant of and/or unresponsive to conventional trimethoprim-sulfamethoxazole or pentamidine therapy." | 3.68 | Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. ( Boylen, CT; Gilman, TM; Heseltine, PN; Paulson, YJ; Sharma, OP, 1992) |
| "The dose limiting toxicity of difluoromethylornithine (DFMO), when administered by continuous infusion, is thrombocytopenia." | 3.68 | Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. ( Ajani, JA; Grossie, VB; Nishioka, K; Ota, DM, 1991) |
| "The purpose of this study was to evaluate the effect of a concomitant infusion of ornithine on the difluoromethylornithine (DFMO)-induced thrombocytopenia and antitumor activity." | 3.67 | Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. ( Ajani, JA; Chang, TH; Grossie, VB; Nishioka, K; Ota, DM; Patenia, D, 1989) |
| "Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and human leukocyte interferon (IFN-alpha) have synergistic anti-tumor activities in vivo in B 16 melanoma and in vitro against several human cancer cell lines." | 3.67 | Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. ( Benjamin, R; Gutterman, J; Kantarjian, H; Plager, C; Quesada, J; Talpaz, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, JR | 1 |
| O'Brien, TG | 1 |
| Skorupski, KA | 1 |
| Krick, EL | 1 |
| Reiter, AM | 1 |
| Jennings, MW | 1 |
| Jurney, CH | 1 |
| Shofer, FS | 1 |
| Paulson, YJ | 1 |
| Gilman, TM | 1 |
| Heseltine, PN | 1 |
| Sharma, OP | 1 |
| Boylen, CT | 1 |
| Grossie, VB | 3 |
| Ota, DM | 3 |
| Ajani, JA | 3 |
| Nishioka, K | 3 |
| Chang, TH | 1 |
| Patenia, D | 1 |
| Levin, B | 1 |
| Splinter, TA | 1 |
| Romijn, JC | 1 |
| Talpaz, M | 1 |
| Plager, C | 1 |
| Quesada, J | 1 |
| Benjamin, R | 1 |
| Kantarjian, H | 1 |
| Gutterman, J | 1 |
| Levin, VA | 1 |
| Chamberlain, MC | 1 |
| Prados, MD | 1 |
| Choucair, AK | 1 |
| Berger, MS | 1 |
| Silver, P | 1 |
| Seager, M | 1 |
| Gutin, PH | 1 |
| Davis, RL | 1 |
| Wilson, CB | 1 |
8 other studies available for eflornithine and Thrombopenia
| Article | Year |
|---|---|
Polyamine inhibitors for treatment of feline oral squamous cell carcinoma: a proof-of-concept study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Eflornithine; Evoked P | 2013 |
Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Eflornithine; Female; Hearing Disorders; Humans; Male; Pn | 1992 |
Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.
Topics: Animals; Biogenic Polyamines; Drug Therapy, Combination; Eflornithine; Kidney; Liver; Male; Ornithin | 1991 |
Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity.
Topics: Animals; Biogenic Polyamines; Eflornithine; Male; Ornithine; Rats; Rats, Inbred F344; Sarcoma, Exper | 1989 |
Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
Topics: Eflornithine; Erythrocytes; Humans; Infusions, Intravenous; Platelet Count; Polyamines; Statistics a | 1989 |
Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Deafness | 1986 |
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Gastrointestinal Diseases | 1986 |
Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Drug Eval | 1987 |